GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO)

Market Cap	585.76B
Revenue (ttm)	37.49B
Net Income (ttm)	9.28B
Shares Out	n/a
EPS (ttm)	54.76
PE Ratio	63.15
Forward PE	56.33
Dividend	54.00 (1.64%)
Ex-Dividend Date	May 30, 2025

Volume	498,509
Average Volume	143,647
Open	3,324.90
Previous Close	3,301.90
Day's Range	3,292.80 - 3,498.80
52-Week Range	1,921.00 - 3,515.70
Beta	0.04
RSI	56.48
Earnings Date	Aug 1, 2025

About NSE:GLAXO

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. It provides vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease; Boostr...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1924
• Employees: 3,113
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: GLAXO

Financial Performance

In 2024, NSE:GLAXO's revenue was 37.49 billion, an increase of 8.56% compared to the previous year's 34.54 billion. Earnings were 9.28 billion, an increase of 57.23%.